| Literature DB >> 26858718 |
Sakshi Malik1, Muzamil Yaqub Want1, Amit Awasthi1.
Abstract
γδ (gamma-delta) T cells, a small population of unconventional T cells, have been found in central nervous system lesions of multiple sclerosis (MS) patients, but their function in disease activity is not clearly understood. Previous studies in experimental autoimmune encephalomyelitis (EAE) were inconsistent in identifying their specific roles in suppressing or promoting disease pathogenesis. Emerging advancements in the biology of γδ T cells especially in the context of their being the major initial producers of IL-17, suggested their crucial role in pathogenesis of EAE. In addition, γδ T cells express high levels of IL-23R and IL-1R, which further enhance their effector functions in the pathogenesis of EAE. Nonetheless, activated heterogeneous γδ T cells display functional dichotomy, which is crucial in determining the outcomes of tissue inflammation in EAE. In this review, we discussed recent advances in understanding the biology of γδ T cells in tissue inflammation as well as their roles in suppressing or promoting the development of EAE.Entities:
Keywords: Th17 cells; autoimmunity; cytokines; gamma–delta T cells; inflammation
Year: 2016 PMID: 26858718 PMCID: PMC4731487 DOI: 10.3389/fimmu.2016.00014
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Figure 1Peripherally primed γδ T cells execute their effector functions in the CNS in EAE. TLRs and NLRs activated dendritic cells (DCs) and macrophages produce proinflammatory cytokines, such as IL-6, IL-23 and IL-1β. IL-23 and IL-1β are sensed by IL-23R-expressing γδ T cells, which in turn produce early burst of IL-17 during early phase of EAE. On the other hand, IL-6 together with TGF-β induce the differentiation of Th17 cells. γδT17 cells produce IL-21, which further amplify their own generation and also amplify the generation of Th17 cells. Differentiated γδT17 and αβ Th17 cells breach the blood brain barrier to execute their effector functions within the CNS during EAE. Activated microglia/macrophages produce IL-23 within the CNS to promote the generation of γδT17 and Th17 cells. Inflammatory γδT17 cells promote CNS injury in EAE by enhancing the effector functions of Th17 cells and restraining the suppressive functions of Tregs cells.
Figure 2Dendritic cell-derived IL-23, IL-1β, and IL-18 mediates induction of effector γδT17 cells. Ligation of TLRs on the surface of DCs induces caspase-1 activation in inflammasome-dependent manner. Activated caspase-1 cleaves pro IL-1β and IL-18 into their active forms as shown in the figure. Activated DCs also produce IL-23, which together with IL-1β or IL-18 promote the induction of proinflammatory cytokines, such as IL-17, GM-CSF, IL-21, and IL-22. These effector γδ T cells initiate disease induction and help αβ+ CD4+ T cells to induce EAE.
Major γδ T cells subset in mouse.
| γ/δ usage | Characteristic | Tissue location |
|---|---|---|
| Vγ1 | Produce IL-4. Regulatory functions in EAE by promoting Treg cells functions ( | Majorly found in circulation, lymphatics, spleen, lymph nodes |
| Vγ4 | Produce IL-17 and express IL-23R. Promote EAE and CIA. Also promote virus-induced encephalitis ( | Lymphoid tissue and lung, also found in CNS in EAE |
| Vγ5 | Regulation of skin inflammation by maintaining the epidermal homeostasis ( | Skin and epidermis |
| Vγ6 | Produce IL-17, IL-22, IFN-γ, and express IL-23R ( | Mucosal tissues, reproductive tract, tongue, lung and kidney. Also detected in CNS during EAE |
| Vγ7 | Prevent colitis by protecting intestinal barrier functions ( | IEL and intestine |
Chief findings of γδ T cells in EAE.
| Gene deficiency/treatment | Consequence | Effect in EAE |
|---|---|---|
| Anti-γδ T cells (clone GL3) monoclonal antibody treatment in EAE | Reduction in disease pathology. Significant reduction in clinical sign in acute phase of EAE | Protection ( |
| Anti-γδ T cells (clone UC7-13D5) monoclonal antibody treatment in EAE | Significant reduction in demyelination and reduction in limb paresis | Protection ( |
| Active EAE development in delta (d) chain-deficient mice | Significant reduction in clinical score of EAE with enhanced frequency of Foxp3+ Tregs | Protection ( |
| EAE induction by adoptively transferring MOG-specific Wt T cells into delta (d) chain-deficient mice | Significant reduction in clinical score of EAE with no cellular infiltration in CNS | Protection ( |
| MBP-specific γδ T cells depleted (clone: GL3) lymph node cells were adoptively transferred to induce EAE | Significant reduction in clinical score in EAE with a significant reduction in IL-12 production | Protection ( |
| Activation of Vγ4 subset with anti-Vγ4 TCR (UC3) antibody treatment in EAE | Worsen EAE with enhanced IL-17 response | Promote EAE ( |
| Activation of Vγ1 subset by anti-Vγ1 TCR antibody (2.11) treatment in EAE | Significant reduction in clinical score of EAE with less proinflammatory cytokines production | Protection ( |
| EAE in IL-23R-deficient mice and effect of IL-23–IL-23R axis on γδ T cells | IL-23R-deficient mice are resistant to EAE. γδ T cells constitutively express IL-23R. Almost all γδ T cells express IL-23R in CNS in EAE and produce IL-17 | Protection ( |
| EAE in IL-18R-deficeint mice and effect of IL-18R on γδ T cells | IL-18R-deficient mice are protected from EAE. IL-18R−/− failed to produce IL-17 | Protection ( |
| EAE in IL-1R-deficent mice and effect of IL-1R on γδ T cells | IL-1R-deficient mice are protected from EAE. IL-1R1−/− γδ T cells are defective in IL-17 and GM-CSF production in EAE | Protection ( |
| EAE in caspase-1-deficient mice and effect of caspase-1 on γδ T cells | Significantly reduced clinical sign of EAE. Defective production of IL-17 and GM-CSF from caspase-1-deficient γδ T cells | Protection ( |